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Hemodialysis vascular access: An ounce of prevention
EDITORIAL
Chronic maintenance hemodialysis requires repeated reliable
access to the systemic circulation. The United States Renal Data
Service reports that hemodialysis access failure continues to be
the most frequent cause of hospitalization in ESRD patients in
the United States [1, 2]. In addition, in some centers it accounts
for the largest number of hospital days [3]. Thus, failed hemodi-
alysis access is not only a major cause of patient morbidity, but
also a significant financial liability, estimated to cost the health
care system in the United States almost 1 billion dollars per year
[4]. It is not surprising that the National Kidney Foundation
identified hemodialysis access as one of the four topics to be
addressed by the dialysis outcomes quality initiative (DOQI) [1].
Ideally, access to the systemic circulation should accommodate
a flow rate adequate for the hemodialysis prescription, remain
usable for a long period of time, and have a low complication rate.
No access meets all these criteria. Native arterio-venous (A-V)
fistulas come closest, but even they are associated with some
complications. Furthermore, in the United States, as the number
of patients undergoing dialysis for ESRD has grown, the use of
native A-V fistulas has declined and the use of synthetic A-V
grafts for permanent vascular access has increased [2]. Unfortu-
nately, patency rates for A-V grafts are inferior to those of native
A-V fistulas, and complication rates are at least threefold greater
[1, 2, 4—6].
The primary complication, accounting for 90% of access dys-
function of both A-V fistulas and grafts, is vascular access
thrombosis. In more than 90% of instances, vascular access
thrombosis is mediated by a venous outflow stenosis [1, 5—9].
These venous stenoses, caused by endothelial and vascular
smooth muscle hyperplasia of the vein wall, occur in areas marked
by turbulence in the venous system. Although they may develop at
sites of vein bifurcation and vein injury associated with central
vein cannulation, they are most common at the vein graft anas-
tomosis in A-V grafts [1, 8—10]. Innovative strategies to minimize
access thrombosis to date have borrowed a page from the
cardiologists: with intensive monitoring using access flows and
pressures, venous outflow stenosis can be prospectively identified
and anatomically treated [1, 7—11]. While this significantly im-
proves access patency, it is costly and may increase patient
morbidity. In addition, it does not address the issue of why this
phenomenon occurs and how it can be prevented.
The prevailing consensus is that venous stenosis is caused by
endothelial injury and vascular smooth muscle hyperplasia in
areas where flow turbulence is created. While many instances of
outflow stenoses do occur at such locations, very little stenosis
occurs at the equally turbulent artery graft anastomosis or at the
site of the artery vein anastomosis in A-V ñstulas. Thus, additional
factors must be present for hyperplasia to occur. Venipuncture in
the hemodialysis access forms a platelet plug with the exposure of
the downstream vessel to a host of platelet-associated cytokines
such as platelet-derived growth factor (PDGF). In this issue of
Kidney International, Himmelfarh and Couper take the first steps
in elucidating the causes of this phenomenon [12]. Previously:,
Sreedhara and associates reported that high-dose dipyridamole
decreased access thrombosis in new, but not previously estab-
lished, A-V grafts [13]. The observations of Himmelfarb and
Couper suggest that the mechanism for this effect may not be
related to the effect of dipyridamole on coagulation, but rather to
a contributory effect of dipyridamole on the inhibition of platelet
derived cytokines (PDGF and others) that act on the vessel wall.
The theory that vascular smooth muscle hyperplasia reflects "a
response to injury" in which platelet-derived growth factor is
prominent suggests that this pathway to vein stenosis may be
preventable. It has been disappointing that while vast amounts of
research and development assets, by both industry and the NIH,
have been directed at coronary stenosis post-percutaneous trans-
luminal coronary angioplasty, almost no basic cellular or molec-
ular research has been funded for the problem of hemodialysis
vascular access stenosis.
As previously suggested by Sukhatme, it is time to apply the
tools of cellular and molecular biology to the clinical problem of
vascular access stenosis [14]. The role of vitamin E and other
agents in addition to dipyridamole must be explored, and clinical
trials using radiotherapy to prevent smooth muscle vascular
hyperplasia are needed.
As outlined in the DOQI Practice Guidelines, a return to
primary A-V fistulas will reduce access problems, but even fistulas
fail because of endothelial injury and vascular smooth muscle
hyperplasia. Active efforts to understand and prevent the basic
causes of venous stenoses are needed. As remarked long ago, an
ounce of prevention is worth many pounds of cure.
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